<DOC>
	<DOCNO>NCT01189500</DOCNO>
	<brief_summary>The goal study evaluate effect multiple dos Desvenlafaxine SR pharmacokinetics Tamoxifen endoxifen coadministered healthy post-menopausal female subject . This study also evaluate safety tolerability Desvenlafaxine SR Tamoxifen coadministered healthy post-menopausal female subject .</brief_summary>
	<brief_title>Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release ( DVS SR ) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Healthy postmenopausal female subject , least 45 year age , confirm postmenopausal status Hysterectomized subject Body Mass Index ( BMI ) less equal 34.0 kg/m2 Nonsmoker smoker few 5 cigarette per day determine history An informed consent document sign date subject History significant blood , kidney , endocrine , lung , gastrointestinal , heart , liver , psychiatric , neurologic , allergic disease Presence history deep vein thrombosis transient ischemic attack History seizure disorder Presence history glaucoma increase intraocular pressure Allergy unable tolerate tamoxifen , desvenlafaxine , venlafaxine History substance abuse within 1 year study A positive urine drug screen Treatment investigational drug within 30 day Consumption grapefruit grapefruit relate citrus fruit 12 lead ECG demonstrate QTc &gt; 450 msec screen Pregnant nursing female Use prescription nonprescription drug dietary supplement History sensitivity heparin heparin induce thrombocytopenia Severe acute chronic medical psychiatric condition laboratory abnormality Use CYP 2D6 inhibitor CYP 3A4 inhibitors/inducers</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>genetic testing</keyword>
	<keyword>CYP 2D6</keyword>
</DOC>